These products are intended to be sterile. Ophthalmic drug products pose a potential heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses.

Phase 2 results were positive for ILYX-002, a topical immunomodulator for moderate to severe dry eye disease associated with systemic autoimmune or inflammatory conditions, according to a press ...